IL-2 muteins and uses thereof
The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.
1. A method of increasing I regulatory cell proliferation in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a peptide comprising the amino acid sequence of SEQ ID NO: 26 wherein the I regulatory cell proliferation is increased in the subject.
2. The method of claim 1 , wherein the peptide further comprises a N-terminal leader peptide having the amino acid sequence of SEQ. ID. No: 7.
3. The method of claim 1 , wherein the peptide further comprises a linker peptide at the C-terminus.
4. The method of claim 3 , wherein the linker peptide comprises the sequence of (GGGGS) n , wherein n is 1, 2, 3, or 4.
5. The method of claim 1 , wherein the peptide further comprises a Fc peptide.
6. The method of claim 5 , wherein the Fc peptide comprises the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 15.
7. The method of claim 5 , wherein the peptide further comprises a leader peptide having the sequence of SEQ. ID. No: 7 at the N-terminus of the peptide.
8. The method of claim 5 , wherein the Fc peptide is at the C-terminus of the peptide.
9. The method of claim 5 , wherein the Fc peptide is at the N-terminus of the peptide.
10. The method of claim 5 , wherein the peptide further comprises a linker peptide that links the peptide of SEQ ID NO: 26 and the Fc peptide.
11. The method of claim 10 , wherein the peptide further comprises a N-terminal leader peptide having the amino acid sequence of SEQ. ID. No: 7 at the N terminus.
12. The method of claim 10 , wherein the linker peptide comprises the sequence of is (GGGGS) n , wherein n is 1, 2, 3, or 4.
13. The method of claim 10 , wherein the Fc peptide comprises the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 15.
14. The method of claim 10 , wherein the Fc peptide is at the C-terminus of the peptide.
15. The method of claim 10 , wherein the Fc peptide is at the N-terminus of the peptide.
16. The method of claim 10 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 40.
17. The method of claim 1 wherein the method further comprises activating the T regulatory cells.
18. A method of activating T regulatory cells in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a peptide comprising the amino acid sequence of SEQ ID NO: 26, wherein the I regulatory cells are activated in the subject.
19. The method of claim 2 , wherein the peptide further comprises a Fc peptide.
20. The method of claim 19 , wherein the Fc peptide is at the C-terminus or the N-terminus of the peptide.
21. The method of claim 19 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 40.
22. The method of claim 1 , wherein the peptide further comprises a linker peptide at the N-terminus.
23. The method of claim 14 , wherein the peptide linker links the N-terminus of the Fc peptide to the C-terminus of the peptide.
24. The method of claim 15 , wherein the peptide linker links the C-terminus of the Fc peptide to the N-terminus of the peptide.
25. The method of claim 22 , wherein the linker peptide comprises the sequence of (GGGGS) n , wherein n is 1, 2, 3, or 4.
26. The method of claim 23 , wherein the linker peptide comprises the sequence of (GGGGS) n , wherein n is 1, 2, 3, or 4.
27. The method of claim 24 , wherein the linker peptide comprises the sequence of (GGGGS) n , wherein n is 1, 2, 3, or 4.